| Heterogeneity and treatment landscape of ovarian carcinoma AC Veneziani, E Gonzalez-Ochoa, H Alqaisi, A Madariaga, G Bhat, ... Nature Reviews Clinical Oncology 20 (12), 820-842, 2023 | 72 | 2023 |
| Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer AC Veneziani, C Scott, MJ Wakefield, AV Tinker, S Lheureux Therapeutic Advances in Medical Oncology 15, 17588359231157644, 2023 | 20 | 2023 |
| Mirvetuximab soravtansine in platinum-resistant ovarian cancer E Gonzalez-Ochoa, AC Veneziani, AM Oza Clinical Medicine Insights: Oncology 17, 11795549231187264, 2023 | 17 | 2023 |
| Predicting the necessity of adding catheters to intracavitary brachytherapy for women undergoing definitive chemoradiation for locally advanced cervical cancer DMF Palhares, DG Marconi, TL de Azevedo, CB Hess, JHTG Fregnani, ... Brachytherapy 17 (6), 935-943, 2018 | 10 | 2018 |
| Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial. A Veneziani, S Lheureux, H Alqaisi, G Bhat, I Colombo, E Gonzalez, ... Journal of Clinical Oncology 40 (16_suppl), 5505-5505, 2022 | 9 | 2022 |
| Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup CL Creutzberg, JW Kim, G Eminowicz, E Allanson, L Eberst, SI Kim, ... The Lancet Oncology 25 (9), e420-e431, 2024 | 4 | 2024 |
| Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile AC Veneziani, S Sneha, AM Oza Clinical Cancer Research 30 (8), 1434-1437, 2024 | 3 | 2024 |
| Emerging peptide therapeutics for the treatment of ovarian cancer AC Veneziani, E Gonzalez-Ochoa, AM Oza Expert Opinion on Emerging Drugs 28 (2), 129-144, 2023 | 3 | 2023 |
| Taking the road less traveled: following molecular trail markers AC Veneziani, AM Oza Clinical Cancer Research 28 (20), 4357-4359, 2022 | 2 | 2022 |
| A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives CDH Lopes, C Braganca Xavier, C Torrado, AC Veneziani, TBC Megid Journal of Immunotherapy and Precision Oncology 7 (4), 283-299, 2024 | 1 | 2024 |
| Discrepancies in breast cancer’s oncological outcomes between public and private institutions in the southeast region of Brazil: A retrospective cohort study DAP Andrade, AC Veneziani, CE Paiva, R Reis, CAF Filho, AON Sanches, ... Frontiers in Oncology 13, 1169982, 2023 | 1 | 2023 |
| Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center. DDA Preto, AON Sanches, AWA Barroso, ACM Carbinatto, AL Veneziani, ... Journal of Clinical Oncology 37 (15_suppl), e12105-e12105, 2019 | 1 | 2019 |
| EV381/# 555 Comprehensive genomic profiling and dynamic monitoring of circulating tumor DNA in patients with small cell carcinoma of the ovary, hypercalcemic type B Grant, A Veneziani, AK Pannu, T May, A Msan, P Sliwo, B Clarke, ... International Journal of Gynecological Cancer 34, A282-A283, 2024 | | 2024 |
| Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers A Madariaga, N Jivraj, PS Pina, F Somji, T Truong, S Melwani, M Lovas, ... International Journal of Gynecological Cancer 34 (10), 1612-1618, 2024 | | 2024 |
| Molecular characterization of cervical cancer histological subtypes: The VENUS study. D Braik, H Alqaisi, V Garg, P Soberanis Pina, L Valente Lage, ... Journal of Clinical Oncology 42 (16_suppl), 5537-5537, 2024 | | 2024 |
| Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study. V Garg, H Alqaisi, P Soberanis Pina, A Veneziani, AK Pannu, B Grant, ... Journal of Clinical Oncology 42 (16_suppl), 12076-12076, 2024 | | 2024 |
| Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching. B Grant, AK Pannu, V Bowering, A Veneziani, P Soberanis Pina, ... Journal of Clinical Oncology 42 (16_suppl), 5523-5523, 2024 | | 2024 |
| Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 … AC Veneziani, H Alqaisi, DG Millar, I Colombo, E Gonzalez-Ochoa, ... Cancer Research 84 (5_Supplement_2), A074-A074, 2024 | | 2024 |
| Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial AC Veneziani, H Alqaisi, DG Millar, I Colombo, E Gonzalez-Ochoa, ... CANCER RESEARCH 84 (5), 2024 | | 2024 |
| 806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers AM Urrutia, N Jivraj, PS Pina, F Somji, T Truon, S Melwani, M Lovas, ... Annals of Oncology 34, S537, 2023 | | 2023 |
